BackgroundWe aimed to explore the surgical outcomes of major lower extremity amputation (MLEA) and influencing factors at an academic tertiary referral centre in north Jordan, optimistically providing a platform for future health care policies and initiatives to improve the outcomes of MLEA in Jordan.MethodsClinical records of patients who had undergone MLEA between January 2012 and December 2017 were identified and retrospectively reviewed. International Classification of Diseases codes were used to identify the study cohort from a prospectively maintained computerised database. We included adult patients of both genders who underwent amputations for ischemic lower limb (acute and chronic) and diabetic foot syndrome (DFS). We excluded patients for whom MLEA surgery was performed for other indications (trauma and tumors). Outcomes of interest included patient demographics and comorbidities, type of amputation and indications, length of hospital stay (LOS), the need for revision surgery (ipsilateral conversion to a higher level of amputation), and cumulative mortality rate at 1 year. The impact of the operating surgeon’s specialty (vascular vs. non-vascular surgeon) on outcomes was evaluated.ResultsThe study cohort comprised 140 patients who underwent MLEA (110 below-knee amputations [BKA] and 30 above-knee amputations [AKA]; ratio: 3:1; 86 men; 54 women; mean age, 62.9 ± 1.1 years). Comorbidities included diabetes, hypertension, dyslipidaemia, ischaemic heart disease, congestive heart failure, chronic kidney disease, stroke, and Buerger disease. The only associated comorbidity was chronic kidney disease, which was more prevalent among BKA patients (p = 0.047). Indications for MLEA included DFS, and lower limb ischaemia. Acute limb ischaemia was more likely to be an indication for AKA (p = 0.006). LOS was considerably longer for AKA (p = 0.035). The cumulative mortality rate at 1 year was 30.7%. Revision surgery rates and LOS improved significantly with increased rate of vascular surgeon-led MLEA.ConclusionsIn developing countries, the adverse impact of MLEA is increased because of limited resources and increased prevalence of diabetes-related foot complications. Vascular surgeon-led MLEA is associated with decreased revision rates, LOS and possibly improved outcomes, particularly when it is performed for vascular insufficiency. It is important to formulate national health care policies to improve patient outcomes in these countries.
ObjectiveThe aim of this study was to evaluate the incidence of postoperative nausea
and vomiting (PONV) after fast-track cardiac anesthesia (FTCA) in the first
24-48 hours in the cardiac intensive care unit (CICU) after open-heart
surgery, risk factors for PONV and its influence on CICU length of stay.MethodsA prospective observational study from January 1, 2013 to the end of December
2015 was performed in the CICU of a university hospital in the north of
Jordan and Queen Alia Heart Institute, Amman, Jordan. Three hundred
consecutive patients undergoing fast-track cardiac anesthesia in elective
cardiac surgery were enrolled in the study. Nausea and vomiting were
assessed after tracheal extubation, which was performed within 6-10 hours
after surgery and during the first 24-48 hours in the CICU. Metoclopramide
10 mg intravenously was used as the initial antiemetic drug, but ondansetron
4 mg intravenously was also used as second line of management.ResultsNausea was reported in 46 (15.3%) patients, and vomiting in 31 (10.3%). Among
females, 38 (33.9%) patients developed nausea and 20 (17.9%) developed
vomiting. Among males, 8 (4.3%) patients developed nausea and 11 (5.9%)
developed vomiting.ConclusionPONV are relatively low after FTCA and the prophylactic administration of
antiemetic drug before anesthesia or after extubation is not necessary.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.